| ProMetic Life Sciences Inc. - Product Pipeline Review - 2012 |
| Publication Date |
Aug 2012 |
| Publisher |
Global Markets Direct |
| Product Type |
Report |
| Pages |
89 |
| Single User License |
$
1500.00 |
| Site User License |
$
3000.00 |
| Corporate User License |
$
4500.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase. |
ProMetic Life Sciences Inc. - Product Pipeline Review - 2012
Summary
Global Markets Direct’s pharmaceuticals report, “ProMetic Life Sciences Inc. - Product Pipeline Review - 2012” provides data on the ProMetic Life Sciences Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ProMetic Life Sciences Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ProMetic Life Sciences Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- ProMetic Life Sciences Inc. - Brief ProMetic Life Sciences Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ProMetic Life Sciences Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ProMetic Life Sciences Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ProMetic Life Sciences Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate ProMetic Life Sciences Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ProMetic Life Sciences Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ProMetic Life Sciences Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ProMetic Life Sciences Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ProMetic Life Sciences Inc. and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of ProMetic Life Sciences Inc.; ProMetic Life Sciences Inc. - Key Therapeutics; ProMetic Life Sciences Inc. - Pipeline Overview and Promising Molecules; ProMetic Life Sciences Inc. - News; ProMetic Life Sciences Inc. - Latest Updates; ProMetic Life Sciences Inc. - Pipeline; ProMetic Life Sciences Inc. - Discontinued/Dormant Projects
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
ProMetic Life Sciences Inc. Snapshot 7
ProMetic Life Sciences Inc. Overview 7
Key Information 7
Key Facts 7
ProMetic Life Sciences Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
ProMetic Life Sciences Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
ProMetic Life Sciences Inc. - Pipeline Products Glance 14
ProMetic Life Sciences Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
ProMetic Life Sciences Inc. - Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
ProMetic Life Sciences Inc. - Drug Profiles 16
PBI-0110 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PBI-0110 + Gemcitabine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PBI-1308 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PBI-1393 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PBI-1402 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
PBI-1522 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PBI-1607 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PBI-1668 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
PBI-1737 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PBI-1737 + Cyclophosphamide 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PBI-4050 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PBI-4265 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PBI-4283 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PBI-4299 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PBI-4419 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PBI-4494 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ProMetic Life Sciences Inc. - Pipeline Analysis 33
ProMetic Life Sciences Inc. - Pipeline Products by Therapeutic Class 33
ProMetic Life Sciences Inc. - Pipeline Products by Route of Administration 34
ProMetic Life Sciences Inc. - Pipeline Products By Mechanism of Action 35
ProMetic Life Sciences Inc. - Recent Pipeline Updates 36
ProMetic Life Sciences Inc. - Dormant Projects 37
ProMetic Life Sciences Inc. - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Financial Deals Landscape 39
ProMetic Life Sciences Inc., Deals Summary 39
ProMetic Life Sciences Inc., Pharmaceuticals & Healthcare, Deal Details 41
Partnerships 41
ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 41
ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 43
ProMetic Enters Into Strategic Agreement With Allist Pharma For PBI-1402 And PBI-4419 45
Novozymes Enters Into Co-Marketing Agreement With ProMetic Life Sciences 47
ProMetic Life Sciences Enters Into Co-Development Agreement With Abraxis BioScience 48
HemCon Medical Technologies Enters Into Co-Development Agreement With ProMetic Biosciences 49
ProMetic And Laboratorios Dermatologicos Enter Into Co-Development Agreement 51
ProMetic BioTherapeutics Enters Into Co-Development Agreement With Blue Blood Biotech 52
ProMetic BioTherapeutics Enters Into Co-Development Agreement With Kedrion 53
Novartis Enters Into Co-Development Agreement With ProMetic Biosciences 54
ProMetic BioTherapeutics Enters Into Research Agreement With Sartorius 55
Sartorius Enters Into Co-Development Agreement With ProMetic BioSciences 56
Licensing Agreements 57
Kedrion Enters Into Licensing Agreement With ProMetic Life Science 57
ProMetic Life Sciences Expands Licensing Agreement With Wuhan Institute 58
ProMetic Enters Into An Agreement With Celgene 59
Abraxis Enters Into License Agreement With ProMetic Life Sciences 60
ProMetic Life Sciences Enters Into Licensing Agreement With Wuhan Institute of Biological Products 62
ProMetic Life Sciences Enters Into Licensing Agreement With Tecpar 63
ProMetic Life Sciences Enters Into Licensing Agreement With Instituto de Tecnologia do Parana 64
Nabi BioPharma Enters Into Agreement With ProMetic Life Sciences 65
Equity Offering 66
ProMetic Life Sciences Completes Private Placement Of Shares For $1 Million 66
ProMetic Life Sciences Completes Private Placement Of $3 Million 68
ProMetic Completes Private Placement Of $7 Million 70
ProMetic Life Sciences Completes Private Placement Of $5 Million 72
ProMetic Completes Private Placement Of $1 Million 74
ProMetic Completes Private Placement Of $6 Million 76
ProMetic Life Sciences Completes Private Placement Of $7.9 Million 78
ProMetic Life Sciences Completes Private Placement Of $6.9 Million 80
ProMetic Completes Private Placement Of $11 Million 82
Debt Offering 84
ProMetic Completes Private Placement Of Senior Notes For $8.9 Million 84
Acquisition 86
ProMetic Life Sciences Acquires Additional 51% Stake In Pathogen Removal And Diagnostic Technologies From American Red Cross 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89
List of TablesList of Tables
ProMetic Life Sciences Inc., Key Information 7
ProMetic Life Sciences Inc., Key Facts 7
ProMetic Life Sciences Inc. - Pipeline by Indication, 2012 9
ProMetic Life Sciences Inc. - Pipeline by Stage of Development, 2012 11
ProMetic Life Sciences Inc. - Monotherapy Products in Pipeline, 2012 12
ProMetic Life Sciences Inc. - Combination Treatment Modalities in Pipeline, 2012 13
ProMetic Life Sciences Inc. - Phase II, 2012 14
ProMetic Life Sciences Inc. - Pre-Clinical, 2012 15
ProMetic Life Sciences Inc. - Pipeline By Therapeutic Class, 2012 33
ProMetic Life Sciences Inc. - Pipeline By Route of Administration, 2012 34
ProMetic Life Sciences Inc. - Pipeline Products By Mechanism of Action, 2012 35
ProMetic Life Sciences Inc. - Recent Pipeline Updates, 2012 36
ProMetic Life Sciences Inc. - Dormant Developmental Projects,2012 37
ProMetic Life Sciences Inc., Other Locations 38
ProMetic Life Sciences Inc., Subsidiaries 38
ProMetic Life Sciences Inc., Deals Summary 39
ProMetic Life Sciences Enters Into Joint Venture Agreement With NantPharma 41
ProMetic Life Sciences Enters Into Co-Development Agreement With Hematech Biotherapeutics 43
ProMetic Enters Into Strategic Agreement With Allist Pharma For PBI-1402 And PBI-4419 45
Novozymes Enters Into Co-Marketing Agreement With ProMetic Life Sciences 47
ProMetic Life Sciences Enters Into Co-Development Agreement With Abraxis BioScience 48
HemCon Medical Technologies Enters Into Co-Development Agreement With ProMetic Biosciences 49
ProMetic And Laboratorios Dermatologicos Enter Into Co-Development Agreement 51
ProMetic BioTherapeutics Enters Into Co-Development Agreement With Blue Blood Biotech 52
ProMetic BioTherapeutics Enters Into Co-Development Agreement With Kedrion 53
Novartis Enters Into Co-Development Agreement With ProMetic Biosciences 54
ProMetic BioTherapeutics Enters Into Research Agreement With Sartorius 55
Sartorius Enters Into Co-Development Agreement With ProMetic BioSciences 56
Kedrion Enters Into Licensing Agreement With ProMetic Life Science 57
ProMetic Life Sciences Expands Licensing Agreement With Wuhan Institute 58
ProMetic Enters Into An Agreement With Celgene 59
Abraxis Enters Into License Agreement With ProMetic Life Sciences 60
ProMetic Life Sciences Enters Into Licensing Agreement With Wuhan Institute of Biological Products 62
ProMetic Life Sciences Enters Into Licensing Agreement With Tecpar 63
ProMetic Life Sciences Enters Into Licensing Agreement With Instituto de Tecnologia do Parana 64
Nabi BioPharma Enters Into Agreement With ProMetic Life Sciences 65
ProMetic Life Sciences Completes Private Placement Of Shares For $1 Million 66
ProMetic Life Sciences Completes Private Placement Of $3 Million 68
ProMetic Completes Private Placement Of $7 Million 70
ProMetic Life Sciences Completes Private Placement Of $5 Million 72
ProMetic Completes Private Placement Of $1 Million 74
ProMetic Completes Private Placement Of $6 Million 76
ProMetic Life Sciences Completes Private Placement Of $7.9 Million 78
ProMetic Life Sciences Completes Private Placement Of $6.9 Million 80
ProMetic Completes Private Placement Of $11 Million 82
ProMetic Completes Private Placement Of Senior Notes For $8.9 Million 84
ProMetic Life Sciences Acquires Additional 51% Stake In Pathogen Removal And Diagnostic Technologies From American Red Cross 86
List of FiguresList of Figures
ProMetic Life Sciences Inc. - Pipeline by Indication, 2012 9
ProMetic Life Sciences Inc. - Pipeline by Stage of Development, 2012 11
ProMetic Life Sciences Inc. - Monotherapy Products in Pipeline, 2012 12
ProMetic Life Sciences Inc. - Combination Treatment Modalities in Pipeline, 2012 13
ProMetic Life Sciences Inc. - Pipeline By Therapeutic Class, 2012 33
ProMetic Life Sciences Inc. - Pipeline By Route of Administration, 2012 34
ProMetic Life Sciences Inc. - Pipeline Products By Mechanism of Action, 2012 35
| Title |
Date |
Price |
|
|
Jan 2013 |
$2000.00 |
|
| By Netscribes (India) Pvt. Ltd. |
| |
|
May 2012 |
$0.00 |
| Medical Devices Market in Russia 2009-2013 |
| By Infiniti Research Ltd |
| Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
|
|
Mar 2010 |
$1500.00 |
|
|
Jan 2013 |
$250.00 |
|
|
Jan 2012 |
$250.00 |
|
|
Jan 2010 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
| 2010 U.S. HMO Medical Centers Industry Report |
| By Barnes Reports |
| The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
|
|
Jan 2010 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
|
|
|
| |
|
| |
|
|
|
